Postoperative Blood Transfusion for Frail Elderly With Hip Fracture

Status Completed

Clinical Trial Summary

Elderly with hip fractures are often frail and discharged from hospital after few days of hospitalisation. Hip fracture surgery is often associated with blood loss, where the patient is at risk of developing anaemia. Low haemoglobin level reduces the body's oxygen transport which causes impaired functional ability and strain on vital organs. Acute anaemia is worse tolerated in elderly, than in younger patients. Therefore this study aims to investigate whether there are effects of an expanded indication for blood transfusion in the frail elderly.

Clinical Trial Description

All elderly patients aged 65 and above who are hospitalised from nursing home or sheltered housing facilities to the Orthopaedic Surgery Ward at Aarhus University Hospital with hip fracture and treated operatively, are eligible for this study. According to sample size calculations 284 patients are needed. Informed consent or deputy informed consent, if the patient is cognitively impaired, is needed. Inclusion is dependent on a haemoglobin measure between 6 and 7 mmol/l 6 days after surgery at the latest. Randomization will be computerised. Randomization will determine intervention with blood transfusion and the measurement of haemoglobin is blinded to the patient, relatives, and endpoint assessor. Both transfusion groups will receive blood when haemoglobin is less than 6 mmol/l, as recommended by the Danish Health and Medicine Authority. Geriatric and Orthopaedic Team (GO-team), consisting of following trained specialists: physiotherapist, nurse, and physician, will conduct medical evaluations, including blood transfusions, from admission until 30 days after surgery. The GO-team will work on weekdays both at the Orthopaedic surgery ward and in the patients home immediately after discharge. In accordance with Aarhus Blood Bank's instructions, blood transfusions are given both under hospitalisation, in the nursing homes and in the sheltered housings. Outcomes are functional ability and mortality during 90 days, and overall quality of life (OQoL) after 30 days and 1 year. The association between physical recovery and OQoL are tested. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01102010
Study type	Interventional
Source	University of Aarhus
Contact
Status	Completed
Phase	Phase 0
Start date	January 2010
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02422355` - A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures
Completed	`NCT02197065` - Pilot Study of Atorvastatin for Orthopedic Surgery Patients	Phase 2
Recruiting	`NCT01934946` - Rehabilitation Care for Hip Fracture	N/A
Completed	`NCT01714336` - Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?	Phase 4
Terminated	`NCT01667913` - Reliability of 6-Minutes Walking Test in Hip Fracture Patients	N/A
Terminated	`NCT01535781` - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?	N/A
Completed	`NCT01174589` - Training of Patients With Hip Fracture	Phase 2
Active, not recruiting	`NCT02362971` - External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture	N/A
Completed	`NCT01738776` - Nutritional Risk Factors for Hip Fracture: a Case Control Study	N/A
Completed	`NCT02591342` - Comparison of a Cemented, Polished Tapered Stem and an Anatomic Stem for Femoral Neck Fracture	N/A
Completed	`NCT01382875` - The Comparison of Comprehensive Multi-disciplinary Program and Conventional Care Program on Fragility Fracture Elderly	Phase 3
Suspended	`NCT00521716` - Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation	N/A
Terminated	`NCT00128115` - Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)	Phase 2
Active, not recruiting	`NCT00345488` - Fast Track Admittance of Hip Fracture Patients	Phase 4
Completed	`NCT02409082` - Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures	N/A
Recruiting	`NCT04626934` - Cognitive Intervention and Rehabilitation Outcomes in Hip Fracture Patients	N/A
Completed	`NCT06001996` - Comparison of Intraoperative- Postoperative Effects of Pericapsular Nerve Block and Fascia Iliaca Block in Hip Fracture
Recruiting	`NCT02635763` - Peripheral Nerve Blocks in Elderly Patients With Hip Fracture	N/A
Completed	`NCT02190903` - A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia	N/A
Completed	`NCT00848913` - Strength Training After Hip Fracture Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.